The DOI matches its Crossref record; 69 of the 70 references it cites were found in a registry or an index.
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Open accessAbstract
BACKGROUND: Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4, has demonstrated an improvement in overall survival in two phase III trials of patients with advanced melanoma. The primary objective of the current trial was to prospectively explore candidate biomarkers from the tumor microenvironment for associations with clinical response to ipilimumab. METHODS: In this randomized, double-blind, phase II biomarker study (ClinicalTrials.gov NCT00261365), 82 pretreated or treatment-naïve patients with unresectable stage III/IV melanoma were induced with 3 or 10 mg/kg ipilimumab every 3 weeks for 4 doses; at Week 24, patients could receive maintenance doses every 12 weeks. Efficacy was evaluated per modified World Health Organization response criteria and safety was assessed continuously. Candidate biomarkers were evaluated in tumor biopsies collected pretreatment and 24 to 72 hours after the second ipilimumab dose. Polymorphisms in immune-related genes were also evaluated. RESULTS: Objective response rate, response patterns, and safety were consistent with previous trials of ipilimumab in melanoma. No associations between genetic polymorphisms and clinical activity were observed. Immunohistochemistry and histology on tumor biopsies revealed significant associations between clinical activity and high baseline expression of FoxP3 (p = 0.014) and indoleamine 2,3-dioxygenase (p = 0.012), and between clinical activity and increase in tumor-infiltrating lymphocytes (TILs) between baseline and 3 weeks after start of treatment (p = 0.005). Microarray analysis of mRNA from tumor samples taken pretreatment and post-treatment demonstrated significant increases in expression of several immune-related genes, and decreases in expression of genes implicated in cancer and melanoma. CONCLUSIONS: Baseline expression of immune-related tumor biomarkers and a post-treatment increase in TILs may be positively associated with ipilimumab clinical activity. The observed pharmacodynamic changes in gene expression warrant further analysis to determine whether treatment-emergent changes in gene expression may be associated with clinical efficacy. Further studies are required to determine the predictive value of these and other potential biomarkers associated with clinical response to ipilimumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Combinatorial biomarker strategies that capture attributes of the host and tumor-immune ecosystem will be essential (Fig. 2; refs.121-124).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [122]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 3×
“5% for 3 mg/kg ipilimumab monotherapy in a phase III trial [4].”
BackgroundResultBioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172 · cited 1×
“0 (Affy package) [32] and q-value package v1.”
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603 · cited 1×
“Gene expression data were normalized using the Robust Multichip Average method [30] and the resulting log2-transformed expression levels were used for subsequent analyses.”
MethodStatistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692 · cited 1×
“A false discovery rate (q-value) approach [31] was used to adjust for multiple testing.”
MethodControl of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187 · cited 1×
“FoxP3 has been identified as a marker of natural and adaptive/induced regulatory T cells (Tregs) [58].”
BackgroundCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“Patients with cancer have higher levels of Tregs in peripheral blood than healthy individuals [59], leading to a suppression of T-cell immunity that has an immunopathologic role in tumor growth [56] and influences prognosis in many cancers [60-63].”
BackgroundTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003 · cited 2×
“Exact 2-sided 95% confidence intervals (CIs) for within-dose-group BORR were calculated using the method of Clopper and Pearson [27].”
Method
Research works printed but not linked: 4
- Richards J, Hwu P, Chin K, Ibrahim R, Berman D, Yellin M, Lowy I, Fahumy F, Hoos A, Wolchok J: Evaluation of treatment guidelines developed for management of immune-related adverse events in ipilimumab clinical protocols [abstract]. Presented at the Perspectives in Melanoma XIII Annual Meeting: Baltimore: O-0006. 2009
- Harmankaya K, Hoos A, Wolchok J, O'Day SJ, Weber JS, Lebbe C, Maio M, Ibrahim R, Humphrey R, Hodi FS: Immune-related response criteria (irRC) identify patients with novel response patterns who have favorable survival among progressors per mWHO criteria [abstract]. Presented at the World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers: 19-21. 2009, 37-Nov ; Berlin, Germany
- Chin K, Ibrahim R, Berman D, Yellin MJ, Lowy I, Lin R, Hoos A: Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab [abstract]. Presented at the 7th World Congress on Melanoma/5th Congress of the European Association of Dermato-Oncology (WCM/EADO). 2009, Joint Meeting 12-16 May 2009; Vienna, Austria
- Gajewski TF, Grimm EA, Nickoloff BJ: New potential therapeutic targets in melanoma. ASCO Educational Book 2008. Edited by: Govindan R. 2008, Alexandria, VA: American Society of Clinical Oncology, 404-407.
Cited by
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
“A retrospective study of patients treated with anti-CTLA-4 reported that a high baseline expression of FoxP3+ Tregs in the tumor was associated with better clinical outcomes (Hamid et al., 2011).”
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
“Intratumorally, a high number of T regulatory cells, the presence of the immunosuppressive enzyme indoleamine 2,3-dioxygenase, and immune-active genetic profile have been associated with benefit from ipilimumab.(82,83) More recently, whole-exome sequencing of tumors from patients treated with CTLA-4 blockade has revea…”
BackgroundNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
“Grade 3 or 4 5 4/5 (80) 1/4 (25) NE (5.”
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
“494 Yes 14 (34) 11 (79) 3 (21) 11 (79) 3 (21) Interval between specimen procurement and treatment initiation (n 1⁄4 41) <1 year 16 (39) 10 (63) 6 (37) 0.”
Metadata
- Authors
- Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., Chasalow, S. D., & Berman, D.
- Affiliations
- Angeles Clinic and Research Institute (US)
- Aarhus University Hospital (DK)
- Hebrew University of Jerusalem (IL)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Oslo University Hospital (NO)
- Karolinska University Hospital (SE)
- Istituto Tumori Bari (IT)
- Instituto Nacional de Enfermedades Neoplásicas (PE)
- Odense University Hospital (DK)
- Bristol-Myers Squibb (United States) (US)
- Corresponding author
- Hamid, Omid
- ORCID
- Venue
- Journal of Translational Medicine
- Published
- 2011-11-28
- Volume
- 9
- Issue
- 1
- Pages
- 204-204
- ISSN
- 1479-5876 (ISSN-L)
- PMC
- PMC3239318
- OpenAlex
- W2138134458
- Cited by
- 534
- References
- 70
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 22 · 2023: 25 · 2022: 25 · 2021: 42 · 2020: 59 · 2019: 41 · 2018: 51 · 2017: 40 · 2016: 53 · 2015: 56 · 2014: 49 · 2013: 47 · 2012: 13
- FWCI
- 17.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0 (tdm)
- Locations
- Journal of Translational Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
- Funders
- Bristol-Myers Squibb
- American Society of Clinical Oncology
- European Society for Medical Oncology
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, advanced melanoma, predictive biomarkers, CTLA-4 blockade, Foxp3, indoleamine 2,3-dioxygenase, tumor-infiltrating lymphocytes, cancer gene expression, immunotherapy response
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Immunohistochemistry, Male, Melanoma, Middle Aged, Neoplasm Staging, Polymorphism, Genetic, Prospective Studies, RNA, Messenger, Skin Neoplasms, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Treatment Outcome, Young Adult, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. https://app.cochat.ai/papers/10.1186/1479-5876-9-204
- The paper
- Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., Chasalow, S. D., & Berman, D. (2011). A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-9-204
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.